How should fluvoxamine be tapered when discontinuing therapy?

Fluvoxamine Tapering Strategy

Fluvoxamine should be tapered gradually rather than stopped abruptly, with dose reductions every 4-7 days as tolerated, and patients must be monitored closely for discontinuation syndrome symptoms including dizziness, nausea, sensory disturbances, and anxiety. 1

Why Gradual Tapering is Essential

Fluvoxamine is specifically identified as one of the SSRIs associated with discontinuation syndrome 2. This occurs because fluvoxamine is a shorter-acting SSRI, making it more prone to withdrawal symptoms compared to longer half-life agents like fluoxetine 3. The discontinuation syndrome can manifest with:

• Somatic symptoms: dizziness, fatigue, lethargy, myalgias, chills, headaches, nausea, vomiting, diarrhea, insomnia, imbalance, vertigo, sensory disturbances, paresthesias
• Psychological symptoms: anxiety, irritability, agitation 2

These symptoms typically emerge within 24-48 hours after missed doses or abrupt discontinuation 3.

Specific Tapering Protocol

Standard Approach

The FDA label provides clear guidance 1:

• Monitor patients closely when discontinuing treatment
• Gradual dose reduction is recommended rather than abrupt cessation whenever possible
• If intolerable symptoms occur during taper, resume the previous dose and decrease more gradually
• The smallest available increments should be used

Practical Tapering Schedule

Based on the evidence for shorter half-life SSRIs 2:

• Reduce dose in the smallest available increments
• Interval between reductions: approximately 1-2 weeks for shorter half-life SSRIs like fluvoxamine
• For patients on doses >100 mg/day (which should be split into two divided doses), taper each component gradually
• Continue monitoring for several weeks after the final dose, as symptoms can emerge days to weeks after discontinuation 4

When Slower Tapering is Needed

Recent research suggests that traditional 2-4 week tapers may be insufficient 5, 6. Consider tapering over months and down to very low doses (below minimum therapeutic doses) for patients who:

• Have been on fluvoxamine long-term (>6 months)
• Have had previous failed discontinuation attempts
• Develop significant withdrawal symptoms during initial dose reductions
• Are elderly or have hepatic impairment (who already have decreased clearance) 1

Critical Monitoring Points

Distinguish Withdrawal from Relapse

Common pitfall: Withdrawal symptoms can mimic depression relapse 3, 4, 6. Key differentiators:

• Withdrawal symptoms typically emerge within days of dose reduction and include prominent physical symptoms (dizziness, sensory disturbances, flu-like symptoms)
• Relapse typically occurs weeks to months after discontinuation and presents with the original psychiatric symptoms without prominent physical symptoms

Special Populations Requiring Extra Caution

Third trimester pregnancy: The FDA label specifically addresses this 1. If treating pregnant women in the third trimester, carefully weigh risks versus benefits of continuing versus tapering. Neonates exposed late in pregnancy may develop complications requiring hospitalization.

Elderly and hepatically impaired patients: These populations have decreased fluvoxamine clearance 1, making them potentially more vulnerable to both accumulation during treatment and withdrawal during discontinuation.

What NOT to Do

• Do not stop abruptly unless medically necessary (e.g., serotonin syndrome, severe adverse reaction)
• Do not use standard 2-4 week tapers as the only approach—many patients need longer 5, 7, 6
• Do not mistake withdrawal symptoms for relapse and restart at full dose unnecessarily 3, 4
• Do not taper during unstable periods or without adequate monitoring support

Managing Withdrawal Symptoms

If withdrawal symptoms emerge during taper 1, 3:

1. Reassure the patient that symptoms are usually transient and self-limiting
2. For mild symptoms: slow the taper rate
3. For severe symptoms: reinstitute the previous dose and taper more gradually
4. Consider holding at a given dose for longer periods (weeks) before the next reduction

Drug Interactions During Tapering

Fluvoxamine has extensive CYP450 interactions (CYP1A2, CYP2C19, CYP2C9, CYP3A4, CYP2D6) 2. When tapering, be aware that:

• Medications whose levels were affected by fluvoxamine may need dose adjustments as fluvoxamine is reduced
• Particularly important for: theophylline, warfarin, benzodiazepines (especially alprazolam and diazepam), and mexiletine 1